Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific corporate action regarding share repurchases executed on July 6, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,250,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,360.5 pence per share; lowest price paid was 1,346.0 pence per share.
- Treasury Holdings (Settled): 471,324,284 shares (8.41% of total issued share capital).
- Treasury Holdings (Including Unsettled): 475,054,284 shares (9.26% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,130,975,348 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,250,000 shares for Treasury. This action increased the proportion of shares held in Treasury to 8.41% of issued capital and 9.26% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural notification of a share repurchase and the resulting capital structure.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (471,324,284 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights held in Treasury (9.26% including unsettled shares) for disclosure threshold calculations.
- Check the number of shares in issue excluding Treasury (5,130,975,348) to ensure accurate denominator usage for shareholder notification requirements under FSA Disclosure and Transparency Rules.
- Review the price range paid (1,346.0 to 1,360.5 pence) to assess the cost of capital reduction relative to market prices on July 6, 2011.